Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol-Reference-Cited by-同舟云学术

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

Published:2009-02-12 Issue:6 Volume:23 Page:1073-1079
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Van der Velden V H J,Corral L,Valsecchi M G,Jansen M W J C,De Lorenzo P,Cazzaniga G,Panzer-Grümayer E R,Schrappe M,Schrauder A,Meyer C,Marschalek R,Nigro L L,Metzler M,Basso G,Mann G,Den Boer M L,Biondi A,Pieters R,Van Dongen J J M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200917.pdf

Reference33 articles.

1. Biondi A, Cimino G, Pieters R, Pui CH . Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24–33.

2. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41–47.

3. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21: 633–641.

4. Li A, Goldwasser MA, Zhou J, Armstrong SA, Wang H, Dalton V et al. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol 2005; 131: 185–192.

5. Stam RW, den Boer ML, Pieters R . Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol 2006; 132: 539–551.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infant Acute Lymphoblastic Leukemia—New Therapeutic Opportunities;International Journal of Molecular Sciences;2024-03-27

2. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia;Leukemia;2024-03-22

3. The prognosis of haploidentical hematopoietic stem cell transplantation in infants and patients under 3 years old with acute leukemia;Clinical Transplantation;2024-02

4. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study;Blood;2023-11-23

5. Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment;Scientific Reports;2023-09-13